ORIGINAL PAPER
Inflammatory syndromes including PIMS-TS in children hospitalised in the Malopolska region of Poland in the first wave of the COVID-19 pandemic
More details
Hide details
1
Stefan Żeromski Specialist Hospital in Krakow, Poland
2
Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
3
Department of Pediatrics, Jagiellonian University Medical College, Krakow, Poland
Submission date: 2020-11-02
Final revision date: 2021-01-14
Acceptance date: 2021-01-25
Publication date: 2021-03-28
Pediatr Pol 2021;96(1):7-15
KEYWORDS
TOPICS
ABSTRACT
Introduction:
To describe cases meeting the criteria of Kawasaki disease (KD), with particular consideration of the first 2 cases of paediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2 infection (PIMS-TS) in patients in the Malopolska region in the first wave of the disease caused by SARS-CoV-2 infection (COVID-19) pandemic.
Material and methods:
From 4 March to 15 July 2020 a total of 11 children meeting KD criteria were hospitalised in the Department of Infectious Diseases and Paediatrics, S. Żeromski Specialist Hospital in Krakow and the Clinic of Children’s Diseases, Department of Paediatrics, Jagiellonian University Medical College in Krakow. This paper analyses the data collected and describes in detail the disease in 2 children with PIMS-TS.
Results:
None of the 11 children who met the criteria of KD had a positive SARS-CoV-2 PCR test on admission. SARS-CoV-2 IgG test results were positive in 2 patients. All children presented with fever, rash, and conjunctivitis; 9 with swollen hands and feet; 8 with mucous membrane changes; 5 with abdominal symptoms; 5 with respiratory symptoms; and 1 with neurological signs. As regards laboratory tests, C-reactive protein (CRP), procalcitonin, lymphocytes, platelets, All were assessed in all patients, albumin in 10/11, lactate dehydrogenase (LDH), fibrinogen in 9/11, troponin and ferritin in 6/11, pro-BNP, D-dimers in 8/11. Echocardiography was performed in all patients and showed coronary artery abnormalities in 4 children. In PIMS-TS significant elevation of procalcitonin, CRP, D-dimers, N-terminal prohormone of brain natriuretic peptide (NT-pro-BNP), and thrombocytopaenia were observed.
Conclusions:
1. Because of the asymptomatic course of SARS-CoV-2 infection in children who subsequently developed PIMS-TS and the absence of any viral genetic material in a sample collected from the upper airways upon PIMS-TS diagnosis, a detailed epidemiological interview and a reliable serology testing for SARS-CoV-2 infection are necessary in each case meeting KD or PIMS-TS criteria.
2. There is a need to look for new factors differentiating PIMS-TS and KD, other than polymerase chain reaction (PCR) and serology tests.
REFERENCES (26)
1.
European Centre for Disease Prevention and Control. Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. Stockholm: ECDC, 2020.
2.
Mahase E. Covid-19: concerns grow over inflammatory syndrome emerging in children. BMJ 2020; 369: m1710.
3.
Rowley AH. Is Kawasaki disease an infectious disorder? Int J Rheum Dis 2018; 21: 20-25.
4.
Jordan-Villegas A, Chang ML, Ramilo O, Mejías A. Concomitant respiratory viral infections in children with Kawasaki disease. Pediatr Infect Dis J 2010; 29: 770-772.
5.
Royal College of Paediatrics and Child Health. Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. UK: 2020.
6.
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395: 1771-1778.
7.
McCrindle BW, MD, Manlhiot C. PhD2. SARS-CoV-2–Related Inflammatory Multisystem Syndrome in Children. JAMA 2020; 324: 246-248.
8.
Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr 2020; 10: 537-540.
9.
Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094.
10.
Feldstein LR, Rose EB, Horwitz SM, et al.; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med 2020; 383: 334-346.
11.
Whittaker E, Bamford A, Kenny J, et al.; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020; 324: 259-269. .
12.
WHO. Multisystem inflammatory syndrome in children. 2020.
13.
McCrindle BW, Rowley AH, Newburger JW, et al.; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Surgery and Anesthesia; and Council on Epidemiology and Prevention. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017; 135: e927-e999.
14.
Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123: e783-789.
15.
Ravelli A, Minoia F, Davì S, et al.; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol 2016; 68: 566-576.
16.
García-Pavón S, Yamazaki-Nakashimada MA, Báez M, et al. Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review. J Pediatr Hematol Oncol 2017; 39: 445-451.
17.
Guarino A, Ashkenazi S, Gendrel D, et al.; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Society for Pediatric Infectious Diseases. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132-152.
18.
de Graeff N, Groot N, Ozen S, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology (Oxford) 2019; 58: 672-682.
19.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606-2612. .
20.
Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191: 499-502.
21.
Ebihara T, Endo R, Ma X, et al. Lack of association between New Haven coronavirus and Kawasaki disease. J Infect Dis 2005; 192: 351-352.
22.
Shirato K, Imada Y, Kawase M, et al. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. J Med Virol 2014; 86: 2146-2153.
23.
Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19): CDC, 2020.
24.
Kim HA, Perrelli A, Ragni A, et al. Vitamin D Deficiency and the Risk of Cerebrovascular Disease. Antioxidants (Basel) 2020; 9: 327.
25.
Zygmunt A, Lewiński A. Niedobór witaminy D a ciężki przebieg COVID-19 – czy istnieje związek? Medycyna Praktyczna 2020; 7-8: 69-73.
26.
Regev T, Antebi M, Eytan D, et al. Pediatric Inflammatory Multisystem Syndrome With Central Nervous System Involvement and Hypocomplementemia Following SARS-COV-2 Infection. Pediatr Infect Dis J 2020; 39: e206-e207.